Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec + Atezolizumab in TNBC and CRC with Liver Metastases
NCT03256344Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Oncolytic Viruses
- Countries
- 6
01
Overview
Phase 1, open-label trial of talimogene laherparepvec in triple-negative breast cancer (TNBC) and colorectal cancer (CRC) (2 cohorts), sponsored by Amgen. Primary endpoint: Dose-Limiting Toxicity. Started Mar 2018; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
triple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03256344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256344.